RxDoctor Payments Data

Sian Yik Lim, MD

Rheumatology · Aiea, HINPI 1992092225

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $867 of the $1,314 with a category attached, or 66.0%. 6 manufacturers reported payments, led by Amgen at 39.5% of the total. Reporting peaked in 2022 at $396 and has fallen 50.3% since, to $197 in 2023. That places this record below the midpoint for rheumatology clinicians in HI, where the typical reported total is $1,399.

$1,314in general payments, 2019–2025

Across 29 payments — averaging $45.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$520
  • Pfizer$328
  • GSK$230
  • Cardinal Health 110 LLC$200
  • Novartis$20
  • AbbVie$17

What the payments were for

  • Consulting fees$43033%
  • Food & beverage$86766%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen12$520
Pfizer10$328
GSK3$230
Cardinal Health 110 LLC2$200
Novartis1$20
AbbVie1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,314 in reported general payments places this provider in the 45th percentile of 21 rheumatology providers in Hawaii.

See all rheumatology providers in Hawaii

Medicare billing

Part B allowed, 2024
$463,669
Medicare patients
600
Services billed
17,257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KrystexxaPegloticase43$1,251,586
Enbrel MiniEtanercept59$442,268
Enbrel SureclickEtanercept38$285,198
Xeljanz XrTofacitinib Citrate48$279,027
RinvoqUpadacitinib22$184,858
Humira(Cf) PenAdalimumab23$165,754
ProliaDenosumab78$137,320
EnbrelEtanercept13$94,023
Cosentyx (2 Syringes)Secukinumab11$79,707
Taltz AutoinjectorIxekizumab11$74,359
TymlosAbaloparatide16$41,981
BenlystaBelimumab11$41,690
Amjevita(Cf) AutoinjectorAdalimumab-Atto12$36,677
Leflunomide470$34,265
Teriparatide11$28,659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenKrystexxa, Prolia, Enbrel$520$1,482,929134 claims
AbbVieRinvoq$17$184,85822 claims
NovartisCosentyx (2 Syringes)$20$79,70711 claims
GSKBenlysta$230$41,69011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 21 rheumatology providers in Hawaii.

Other rheumatology in Aiea

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →